Opus Genetics Inc (IRD)

$4.44 -0.36 (-7.50%)
Market Cap 390.70M
Revenue (ttm) 14.20M
Net Income (ttm) -49.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -349.23%
Debt to Equity Ratio 0.00
Volume 1,400,000
Avg Vol 888,258
Day's Range N/A - N/A
Shares Out 81.40M
Stochastic %K 1%
Beta 0.62
Analysts Strong Sell
Price Target $10.13

Company Profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
signaljumper
signaljumper May. 19 at 5:53 AM
$IRD biotech Index did a correction so also this Stock move down as another biotech Stocks.
0 · Reply
made006
made006 May. 18 at 8:50 PM
$IRD this management suck...where's the lynxs-3 / dim light disturbance trial result? said trial result will be first half 2026 but nothing mentioned at Q1 earning release
0 · Reply
LukeLongley
LukeLongley May. 18 at 7:47 PM
$IRD What the Absolute living fuck is going on with this weakness?? Momentum is DOGSHIT 💩lately !! Couldnt hold $5+ many times like a little college girl .. Get your ass back to $5.20+ or im dumping $190K worth and moving on to next …
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 6:27 PM
$IRD!!! $5.20 TIME!!!!!!!!!!!!!
1 · Reply
TruthTooPower
TruthTooPower May. 18 at 5:58 PM
$IRD!!! I Guess They Don't Want me Around Anymore…
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 4:57 PM
$IRD!!! Break Over VWAP!!! Hell Yeah 🙌
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:57 PM
$IRD!!! Drip Investment Insider Buying!!! ❤️
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:56 PM
$IRD!!! Excellent:
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:35 PM
$IRD!!! With PDT GONE!!! Rock And Roll Baby!!!
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:31 PM
$IRD!!! $GRI !!! Is Going To Start Lighting Up Also!!!
0 · Reply
Latest News on IRD
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

May 13, 2026, 7:00 AM EDT - 5 days ago

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

Opus Genetics price target lowered to $11 from $12 at Citizens

2026-05-13T09:57:18.000Z - 5 days ago

Opus Genetics price target lowered to $11 from $12 at Citizens

Opus Genetics reports Q1 EPS (75c), consensus (14c)

2026-05-12T12:00:32.000Z - 6 days ago

Opus Genetics reports Q1 EPS (75c), consensus (14c)

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 6 days ago

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

May 7, 2026, 4:30 PM EDT - 11 days ago

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

May 7, 2026, 7:00 AM EDT - 11 days ago

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics announces FDA acceptance of OPGx-LCA5 into RDEP program

2026-05-04T21:16:00.000Z - 14 days ago

Opus Genetics announces FDA acceptance of OPGx-LCA5 into RDEP program

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

May 4, 2026, 4:30 PM EDT - 14 days ago

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Opus Genetics price target raised to $10 from $9 at B. Riley

2026-04-30T13:56:08.000Z - 18 days ago

Opus Genetics price target raised to $10 from $9 at B. Riley

Opus Genetics initiated with an Outperform at Citizens

2026-04-28T08:45:12.000Z - 20 days ago

Opus Genetics initiated with an Outperform at Citizens

Opus Genetics management to meet with Piper Sandler

2026-04-27T19:55:56.000Z - 21 days ago

Opus Genetics management to meet with Piper Sandler

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Apr 27, 2026, 8:00 AM EDT - 21 days ago

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Opus Genetics management to meet with B. Riley

2026-04-14T14:50:14.000Z - 4 weeks ago

Opus Genetics management to meet with B. Riley

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 10, 2026, 6:59 AM EDT - 5 weeks ago

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Apr 6, 2026, 7:00 AM EDT - 6 weeks ago

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

2026-03-30T10:22:42.000Z - 7 weeks ago

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

2026-03-30T10:10:51.000Z - 7 weeks ago

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Mar 24, 2026, 7:00 AM EDT - 7 weeks ago

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Oppenheimer bullish on Opus Genetics, initiates with an Outperform

2026-03-16T11:41:19.000Z - 2 months ago

Oppenheimer bullish on Opus Genetics, initiates with an Outperform

Opus Genetics initiated with an Outperform at Oppenheimer

2026-03-16T10:32:04.000Z - 2 months ago

Opus Genetics initiated with an Outperform at Oppenheimer

Opus Genetics files to sell 7.37M shares of common stock for holders

2026-03-13T21:00:32.000Z - 2 months ago

Opus Genetics files to sell 7.37M shares of common stock for holders

Opus Genetics price target raised to $10 from $8 at Wedbush

2026-03-12T12:21:25.000Z - 2 months ago

Opus Genetics price target raised to $10 from $8 at Wedbush

Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year

2026-03-10T11:06:29.000Z - 2 months ago

Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Mar 3, 2026, 8:00 AM EST - 2 months ago

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Opus Genetics price target raised to $12 from $7 at BTIG

2026-03-02T12:45:49.000Z - 2 months ago

Opus Genetics price target raised to $12 from $7 at BTIG

Opus Genetics announces initial data from Phase 1/2 study of OPGx-BEST1

2026-02-27T15:22:14.000Z - 2 months ago

Opus Genetics announces initial data from Phase 1/2 study of OPGx-BEST1

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Feb 27, 2026, 10:10 AM EST - 2 months ago

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics says FDA accepts sNDA for phentolamine ophthalmic solution 0.75%

2026-02-25T12:09:04.000Z - 2 months ago

Opus Genetics says FDA accepts sNDA for phentolamine ophthalmic solution 0.75%

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Feb 25, 2026, 6:59 AM EST - 2 months ago

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics prices 7.37M Preferred Stock at $3.39 in private placement

2026-02-13T12:40:37.000Z - 3 months ago

Opus Genetics prices 7.37M Preferred Stock at $3.39 in private placement

Opus Genetics Announces $25 Million Private Placement

Feb 13, 2026, 7:30 AM EST - 3 months ago

Opus Genetics Announces $25 Million Private Placement

Opus Genetics initiated with an Outperform at LifeSci Capital

2026-02-12T12:55:46.000Z - 3 months ago

Opus Genetics initiated with an Outperform at LifeSci Capital

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Feb 2, 2026, 8:00 AM EST - 3 months ago

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Jan 27, 2026, 7:00 AM EST - 3 months ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Opus Genetics Transcript: 44th Annual J.P. Morgan Healthcare conference

Jan 15, 2026, 11:15 AM EST - 4 months ago

Opus Genetics Transcript: 44th Annual J.P. Morgan Healthcare conference

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Jan 8, 2026, 7:00 AM EST - 4 months ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 4:01 PM EST - 5 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 5 months ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Dec 9, 2025, 7:00 AM EST - 5 months ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 20, 2025, 8:00 AM EST - 6 months ago

Opus Genetics to Participate in Upcoming Investment Conferences

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 13, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces $23 Million Registered Direct Offering

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Nov 6, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Oct 2, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics Transcript: Study result

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Opus Genetics Transcript: Study result

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Sep 30, 2025, 7:00 AM EDT - 8 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 18, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 9 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 11 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Transcript: Investor update

Jun 26, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Transcript: Investor update

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 11 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 1 year ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 1 year ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 1 year ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 1 year ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

signaljumper
signaljumper May. 19 at 5:53 AM
$IRD biotech Index did a correction so also this Stock move down as another biotech Stocks.
0 · Reply
made006
made006 May. 18 at 8:50 PM
$IRD this management suck...where's the lynxs-3 / dim light disturbance trial result? said trial result will be first half 2026 but nothing mentioned at Q1 earning release
0 · Reply
LukeLongley
LukeLongley May. 18 at 7:47 PM
$IRD What the Absolute living fuck is going on with this weakness?? Momentum is DOGSHIT 💩lately !! Couldnt hold $5+ many times like a little college girl .. Get your ass back to $5.20+ or im dumping $190K worth and moving on to next …
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 6:27 PM
$IRD!!! $5.20 TIME!!!!!!!!!!!!!
1 · Reply
TruthTooPower
TruthTooPower May. 18 at 5:58 PM
$IRD!!! I Guess They Don't Want me Around Anymore…
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 4:57 PM
$IRD!!! Break Over VWAP!!! Hell Yeah 🙌
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:57 PM
$IRD!!! Drip Investment Insider Buying!!! ❤️
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:56 PM
$IRD!!! Excellent:
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:35 PM
$IRD!!! With PDT GONE!!! Rock And Roll Baby!!!
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:31 PM
$IRD!!! $GRI !!! Is Going To Start Lighting Up Also!!!
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:27 PM
$IRD!!! $HROW
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:20 PM
$IRD!!! Actually $HROW I received it around $7 or $8 I just looked it up…
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:18 PM
$HROW!!! $IRD !!! $HROW I used to own it for a time. It is another optical industry company I bought for $30 a while ago, as it moved up to $50, almost time to get some again… I’m looking for Opus here to give us a new 52-week high shortly...
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 3:10 PM
$IRD!!! With everything that’s going on with Opus. It makes me wonder what do you think this is gonna be worth a year from now?
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 1:40 PM
$IRD!!! !!!!!!!!!$6!!!!!!!!! Is Accurate!!!!!!
0 · Reply
TruthTooPower
TruthTooPower May. 18 at 1:38 PM
$IRD!!! LOAD EM!!!!!!!!!!!!!
0 · Reply
Stockseeking
Stockseeking May. 17 at 1:00 PM
$IRD PDUFA Oct17 cash into 2029 priority review voucher >150 millions
0 · Reply
TruthTooPower
TruthTooPower May. 15 at 7:33 PM
$IRD!!! Get all You Can 🤓🤓🤓
1 · Reply
TheAliAbdul
TheAliAbdul May. 15 at 5:30 PM
$IRD broken on the downside, down 16% past month
0 · Reply
TruthTooPower
TruthTooPower May. 14 at 11:00 AM
$IRD!!! $AIIO !!! Been A Beautiful Month!!!
0 · Reply
Stockseeking
Stockseeking May. 13 at 7:05 PM
$IRD A lot of cash; PDUA; multiple trial updates Huge potential
0 · Reply
TruthTooPower
TruthTooPower May. 13 at 6:47 PM
$IRD!!! 🤓🤓🤓 Is the next $TDIC
0 · Reply